QNRX vs. NUWE, TIVC, CTCX, CHEK, TNON, SINT, HSCS, AMIX, NDRA, and GMVDF
Should you be buying Quoin Pharmaceuticals stock or one of its competitors? The main competitors of Quoin Pharmaceuticals include Nuwellis (NUWE), Tivic Health Systems (TIVC), Carmell (CTCX), Check-Cap (CHEK), Tenon Medical (TNON), Sintx Technologies (SINT), Heart Test Laboratories (HSCS), Autonomix Medical (AMIX), ENDRA Life Sciences (NDRA), and G Medical Innovations (GMVDF). These companies are all part of the "medical equipment" industry.
Quoin Pharmaceuticals vs.
Quoin Pharmaceuticals (NASDAQ:QNRX) and Nuwellis (NASDAQ:NUWE) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations, community ranking, valuation and dividends.
Nuwellis received 17 more outperform votes than Quoin Pharmaceuticals when rated by MarketBeat users. However, 55.56% of users gave Quoin Pharmaceuticals an outperform vote while only 53.66% of users gave Nuwellis an outperform vote.
Quoin Pharmaceuticals has a net margin of 0.00% compared to Nuwellis' net margin of -169.54%. Quoin Pharmaceuticals' return on equity of -125.60% beat Nuwellis' return on equity.
8.6% of Quoin Pharmaceuticals shares are owned by institutional investors. Comparatively, 3.1% of Nuwellis shares are owned by institutional investors. 3.7% of Quoin Pharmaceuticals shares are owned by insiders. Comparatively, 2.6% of Nuwellis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Quoin Pharmaceuticals has higher earnings, but lower revenue than Nuwellis. Quoin Pharmaceuticals is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks.
Quoin Pharmaceuticals has a beta of 1.72, suggesting that its share price is 72% more volatile than the S&P 500. Comparatively, Nuwellis has a beta of 0.31, suggesting that its share price is 69% less volatile than the S&P 500.
Quoin Pharmaceuticals currently has a consensus price target of $4.00, suggesting a potential upside of 1,152.74%. Nuwellis has a consensus price target of $17.00, suggesting a potential upside of 1,207.69%. Given Nuwellis' stronger consensus rating and higher possible upside, analysts plainly believe Nuwellis is more favorable than Quoin Pharmaceuticals.
In the previous week, Nuwellis had 3 more articles in the media than Quoin Pharmaceuticals. MarketBeat recorded 3 mentions for Nuwellis and 0 mentions for Quoin Pharmaceuticals. Quoin Pharmaceuticals' average media sentiment score of 0.00 beat Nuwellis' score of -0.34 indicating that Quoin Pharmaceuticals is being referred to more favorably in the media.
Summary
Quoin Pharmaceuticals beats Nuwellis on 10 of the 17 factors compared between the two stocks.
Get Quoin Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for QNRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Quoin Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:QNRX) was last updated on 2/22/2025 by MarketBeat.com Staff
Free QNRX Stock Alerts